Early effects of sodium valproate monotherapy on serum paraoxonase/arylesterase activities.
OBJECTIVE
Valproic acid (VPA) treatment and paraoxonase1/arylesterase (PON1/Aryl) activities are related to the production of free radicals. Our aim was to study the PON1/Aryl activities in children on VPA therapy.


METHODS
Thirty-two children with seizures and 30 healthy child volunteers took part. Ill children underwent the common laboratory tests, as well as total antioxidant status (TAS), total oxidant status (TOS), lipid profile, liver enzymes and PON1/Aryl activities pre- and post-60 days on VPA therapy (30 mg/kg/24 h), whereas the healthy children were tested just once.


RESULTS
None of the studied biochemical parameters differed between volunteers and children with seizures pretreatment. Liver enzymes, lipids and TOS levels (124+/-30 versus 580+/-40 micromol/L; p<0.001) were significantly elevated, whereas the activities of PON1/Aryl (146+/-43 versus 118+/-40 U/mL/min 120+/-42 versus 98+/-38 KU/mL/min; p<0.01) and TAS levels (436+/-42 versus 288+/-39 micromol/L; p<0.001) were decreased in children after treatment. Additionally, strong negative correlations were found between PON1/Aryl activities, liver enzymes, TOS (r = -0.69) and VPA levels (r = -0.57), whereas PON1/Aryl activities correlated positively with TAS, HDL and Apo A-I in all groups.


CONCLUSIONS
Serum PON1/Aryl activities were decreased after 60 days on VPA treatment, probably due to liver dysfunction and free radicals production by VPA, without excluding the possibility of a direct action of the drug on the enzymes.
Karikas
George A
GA
Department of Medical Laboratories, Technological and Educational Institute of Athens, Athens, Greece.
Schulpis
Kleopatra H
KH
Bartzeliotou
Anastasia
A
Regoutas
Spyros
S
Thanopoulou
Christina
C
Papaevangelou
Vassiliki
V
Giannoulia-Karantana
Aglaia
A
Papassotiriou
Ioannis
I
Fytou-Pallikari
Athena
A
D000975:Antioxidants / Q000378:metabolism; D043303:Aryldialkylphosphatase / Q000097:blood*; D002265:Carboxylic Ester Hydrolases / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D016877:Oxidants / Q000097:blood; D012640:Seizures / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use
D000975:Antioxidants; D008055:Lipids; D016877:Oxidants; D014635:Valproic Acid; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043303:Aryldialkylphosphatase